Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol)

Background: Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been u...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Expert opinion on investigational drugs 2009-10, Vol.18 (10), p.1565-1571
Hauptverfasser: Fechner, Jörg, Ihmsen, Harald, Jeleazcov, Christian, Schüttler, Jürgen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1571
container_issue 10
container_start_page 1565
container_title Expert opinion on investigational drugs
container_volume 18
creator Fechner, Jörg
Ihmsen, Harald
Jeleazcov, Christian
Schüttler, Jürgen
description Background: Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find either a better formulation or a prodrug of propofol. Fospropofol is the first propofol prodrug that has been intensively studied in man. It has been licensed in 2008 by the FDA for monitored anesthetic care sedation. Objectives and methods: This review describes first published study results of fospropofol with regard to its pharmacokinetics/pharmacodynamics, drug safety, tolerability and drug side effects. Using a Medline search all published articles and abstracts containing the words fospropofol or GPI 15715 were included. Results and conclusion: As the impact of an errorness drug assay for propofol liberated from fospropofol is not exactly defined, no clear conclusions can be drawn from the first published pharmacokinetic/pharmacodynamic studies. Fospropofol was well tolerated in the first two clinical studies and no serious side effects were reported. After characterization of the true pharmacokinetic/pharmacodynamics profile, fospropofol, an aqueous solution, has the potential to favorably compare with benzodiazepines for procedural sedation and also may be used for long-term sedation and intravenous anesthesia.
doi_str_mv 10.1517/13543780903193063
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1517_13543780903193063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19758110</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-923ecf883233aca6bf3a02d6ef3e9eb302dc9ceec32f6ae4513d231ef4636aa43</originalsourceid><addsrcrecordid>eNp9kFtLxDAQhYMoXlZ_gC-SR4WtJp1e0RcRb7Dgiz6XaTqxlWxTklbZf2-WFUUEn-Yw853DcBg7luJcpjK_kJAmkBeiFCBLEBlssX2ZJ0mUZ2mxHXS4RwFI9tiB929CxKJMYZftyTJPCynFPjN31g_ODlZbw5vO26ablnOO_ANHcpG3ZqoN8YA0bnrlVvOxJd71o8N36u3kOfbkw27sFP8OOo3nWdR0IW69WpmhDaw5O2Q7Go2no685Yy93t883D9Hi6f7x5noRqUSkY1TGQEoXBcQAqDCrNaCIm4w0UEk1BK1KRaQg1hlSkkpoYpCkkwwyxARmTG5ylbPeO9LV4LolulUlRbVurvrTXPCcbDzDVC-p-XF8VRWAqw3Q9dq6JX5YZ5pqxJWxTjvsVecr-C__8pe9JTRjq9BR9WYn14c-_vnuE1rUkQY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol)</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Access via Taylor &amp; Francis</source><creator>Fechner, Jörg ; Ihmsen, Harald ; Jeleazcov, Christian ; Schüttler, Jürgen</creator><creatorcontrib>Fechner, Jörg ; Ihmsen, Harald ; Jeleazcov, Christian ; Schüttler, Jürgen</creatorcontrib><description>Background: Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find either a better formulation or a prodrug of propofol. Fospropofol is the first propofol prodrug that has been intensively studied in man. It has been licensed in 2008 by the FDA for monitored anesthetic care sedation. Objectives and methods: This review describes first published study results of fospropofol with regard to its pharmacokinetics/pharmacodynamics, drug safety, tolerability and drug side effects. Using a Medline search all published articles and abstracts containing the words fospropofol or GPI 15715 were included. Results and conclusion: As the impact of an errorness drug assay for propofol liberated from fospropofol is not exactly defined, no clear conclusions can be drawn from the first published pharmacokinetic/pharmacodynamic studies. Fospropofol was well tolerated in the first two clinical studies and no serious side effects were reported. After characterization of the true pharmacokinetic/pharmacodynamics profile, fospropofol, an aqueous solution, has the potential to favorably compare with benzodiazepines for procedural sedation and also may be used for long-term sedation and intravenous anesthesia.</description><identifier>ISSN: 1354-3784</identifier><identifier>EISSN: 1744-7658</identifier><identifier>DOI: 10.1517/13543780903193063</identifier><identifier>PMID: 19758110</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Anesthetics, Intravenous - adverse effects ; Anesthetics, Intravenous - pharmacokinetics ; Anesthetics, Intravenous - therapeutic use ; Animals ; Clinical Trials as Topic ; Drug Approval ; fospropofol ; Humans ; intravenous anesthetics ; Prodrugs - adverse effects ; Prodrugs - pharmacokinetics ; Prodrugs - therapeutic use ; propofol ; Propofol - adverse effects ; Propofol - analogs &amp; derivatives ; Propofol - pharmacokinetics ; Propofol - therapeutic use ; propofol prodrug ; Solubility ; United States ; United States Food and Drug Administration</subject><ispartof>Expert opinion on investigational drugs, 2009-10, Vol.18 (10), p.1565-1571</ispartof><rights>Informa UK Ltd 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c405t-923ecf883233aca6bf3a02d6ef3e9eb302dc9ceec32f6ae4513d231ef4636aa43</citedby><cites>FETCH-LOGICAL-c405t-923ecf883233aca6bf3a02d6ef3e9eb302dc9ceec32f6ae4513d231ef4636aa43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/13543780903193063$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/13543780903193063$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,59753,60436,60542</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19758110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fechner, Jörg</creatorcontrib><creatorcontrib>Ihmsen, Harald</creatorcontrib><creatorcontrib>Jeleazcov, Christian</creatorcontrib><creatorcontrib>Schüttler, Jürgen</creatorcontrib><title>Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol)</title><title>Expert opinion on investigational drugs</title><addtitle>Expert Opin Investig Drugs</addtitle><description>Background: Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find either a better formulation or a prodrug of propofol. Fospropofol is the first propofol prodrug that has been intensively studied in man. It has been licensed in 2008 by the FDA for monitored anesthetic care sedation. Objectives and methods: This review describes first published study results of fospropofol with regard to its pharmacokinetics/pharmacodynamics, drug safety, tolerability and drug side effects. Using a Medline search all published articles and abstracts containing the words fospropofol or GPI 15715 were included. Results and conclusion: As the impact of an errorness drug assay for propofol liberated from fospropofol is not exactly defined, no clear conclusions can be drawn from the first published pharmacokinetic/pharmacodynamic studies. Fospropofol was well tolerated in the first two clinical studies and no serious side effects were reported. After characterization of the true pharmacokinetic/pharmacodynamics profile, fospropofol, an aqueous solution, has the potential to favorably compare with benzodiazepines for procedural sedation and also may be used for long-term sedation and intravenous anesthesia.</description><subject>Anesthetics, Intravenous - adverse effects</subject><subject>Anesthetics, Intravenous - pharmacokinetics</subject><subject>Anesthetics, Intravenous - therapeutic use</subject><subject>Animals</subject><subject>Clinical Trials as Topic</subject><subject>Drug Approval</subject><subject>fospropofol</subject><subject>Humans</subject><subject>intravenous anesthetics</subject><subject>Prodrugs - adverse effects</subject><subject>Prodrugs - pharmacokinetics</subject><subject>Prodrugs - therapeutic use</subject><subject>propofol</subject><subject>Propofol - adverse effects</subject><subject>Propofol - analogs &amp; derivatives</subject><subject>Propofol - pharmacokinetics</subject><subject>Propofol - therapeutic use</subject><subject>propofol prodrug</subject><subject>Solubility</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1354-3784</issn><issn>1744-7658</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kFtLxDAQhYMoXlZ_gC-SR4WtJp1e0RcRb7Dgiz6XaTqxlWxTklbZf2-WFUUEn-Yw853DcBg7luJcpjK_kJAmkBeiFCBLEBlssX2ZJ0mUZ2mxHXS4RwFI9tiB929CxKJMYZftyTJPCynFPjN31g_ODlZbw5vO26ablnOO_ANHcpG3ZqoN8YA0bnrlVvOxJd71o8N36u3kOfbkw27sFP8OOo3nWdR0IW69WpmhDaw5O2Q7Go2no685Yy93t883D9Hi6f7x5noRqUSkY1TGQEoXBcQAqDCrNaCIm4w0UEk1BK1KRaQg1hlSkkpoYpCkkwwyxARmTG5ylbPeO9LV4LolulUlRbVurvrTXPCcbDzDVC-p-XF8VRWAqw3Q9dq6JX5YZ5pqxJWxTjvsVecr-C__8pe9JTRjq9BR9WYn14c-_vnuE1rUkQY</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Fechner, Jörg</creator><creator>Ihmsen, Harald</creator><creator>Jeleazcov, Christian</creator><creator>Schüttler, Jürgen</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20091001</creationdate><title>Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol)</title><author>Fechner, Jörg ; Ihmsen, Harald ; Jeleazcov, Christian ; Schüttler, Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-923ecf883233aca6bf3a02d6ef3e9eb302dc9ceec32f6ae4513d231ef4636aa43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Anesthetics, Intravenous - adverse effects</topic><topic>Anesthetics, Intravenous - pharmacokinetics</topic><topic>Anesthetics, Intravenous - therapeutic use</topic><topic>Animals</topic><topic>Clinical Trials as Topic</topic><topic>Drug Approval</topic><topic>fospropofol</topic><topic>Humans</topic><topic>intravenous anesthetics</topic><topic>Prodrugs - adverse effects</topic><topic>Prodrugs - pharmacokinetics</topic><topic>Prodrugs - therapeutic use</topic><topic>propofol</topic><topic>Propofol - adverse effects</topic><topic>Propofol - analogs &amp; derivatives</topic><topic>Propofol - pharmacokinetics</topic><topic>Propofol - therapeutic use</topic><topic>propofol prodrug</topic><topic>Solubility</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fechner, Jörg</creatorcontrib><creatorcontrib>Ihmsen, Harald</creatorcontrib><creatorcontrib>Jeleazcov, Christian</creatorcontrib><creatorcontrib>Schüttler, Jürgen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Expert opinion on investigational drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fechner, Jörg</au><au>Ihmsen, Harald</au><au>Jeleazcov, Christian</au><au>Schüttler, Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol)</atitle><jtitle>Expert opinion on investigational drugs</jtitle><addtitle>Expert Opin Investig Drugs</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>18</volume><issue>10</issue><spage>1565</spage><epage>1571</epage><pages>1565-1571</pages><issn>1354-3784</issn><eissn>1744-7658</eissn><abstract>Background: Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find either a better formulation or a prodrug of propofol. Fospropofol is the first propofol prodrug that has been intensively studied in man. It has been licensed in 2008 by the FDA for monitored anesthetic care sedation. Objectives and methods: This review describes first published study results of fospropofol with regard to its pharmacokinetics/pharmacodynamics, drug safety, tolerability and drug side effects. Using a Medline search all published articles and abstracts containing the words fospropofol or GPI 15715 were included. Results and conclusion: As the impact of an errorness drug assay for propofol liberated from fospropofol is not exactly defined, no clear conclusions can be drawn from the first published pharmacokinetic/pharmacodynamic studies. Fospropofol was well tolerated in the first two clinical studies and no serious side effects were reported. After characterization of the true pharmacokinetic/pharmacodynamics profile, fospropofol, an aqueous solution, has the potential to favorably compare with benzodiazepines for procedural sedation and also may be used for long-term sedation and intravenous anesthesia.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>19758110</pmid><doi>10.1517/13543780903193063</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1354-3784
ispartof Expert opinion on investigational drugs, 2009-10, Vol.18 (10), p.1565-1571
issn 1354-3784
1744-7658
language eng
recordid cdi_crossref_primary_10_1517_13543780903193063
source MEDLINE; Taylor & Francis Medical Library - CRKN; Access via Taylor & Francis
subjects Anesthetics, Intravenous - adverse effects
Anesthetics, Intravenous - pharmacokinetics
Anesthetics, Intravenous - therapeutic use
Animals
Clinical Trials as Topic
Drug Approval
fospropofol
Humans
intravenous anesthetics
Prodrugs - adverse effects
Prodrugs - pharmacokinetics
Prodrugs - therapeutic use
propofol
Propofol - adverse effects
Propofol - analogs & derivatives
Propofol - pharmacokinetics
Propofol - therapeutic use
propofol prodrug
Solubility
United States
United States Food and Drug Administration
title Fospropofol disodium, a water-soluble prodrug of the intravenous anesthetic propofol (2,6-diisopropylphenol)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T04%3A10%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fospropofol%20disodium,%20a%20water-soluble%20prodrug%20of%20the%20intravenous%20anesthetic%20propofol%20(2,6-diisopropylphenol)&rft.jtitle=Expert%20opinion%20on%20investigational%20drugs&rft.au=Fechner,%20J%C3%B6rg&rft.date=2009-10-01&rft.volume=18&rft.issue=10&rft.spage=1565&rft.epage=1571&rft.pages=1565-1571&rft.issn=1354-3784&rft.eissn=1744-7658&rft_id=info:doi/10.1517/13543780903193063&rft_dat=%3Cpubmed_cross%3E19758110%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19758110&rfr_iscdi=true